A dose escalation study of nimotuzumab plus irinotecan as second-line treatment in metastatic colorectal cancer with wild-type K-ras.
Jun Zhou
No relevant relationships to disclose
Lin Shen
No relevant relationships to disclose
Jing Gao
No relevant relationships to disclose